No. 61 AI & data science
Chris Gibson
Co-founder and CEO, Recursion • United States
Scaling drug discovery through high-throughput biology, machine learning, and automated clinical chemistry workflows.
Find on LinkedInThe Signal
He actively communicates the future of tech-enabled biotechnology and AI in drug discovery, providing detailed insights into wet-lab and dry-lab integration.
Who Chris Gibson is
Scaling drug discovery through high-throughput biology, machine learning, and automated clinical chemistry workflows.
He actively communicates the future of tech-enabled biotechnology and AI in drug discovery, providing detailed insights into wet-lab and dry-lab integration.
Loading the full dossier
At a glance
- Role
- Co-founder and CEO
- Organisation
- Recursion
- Platforms
- LinkedIn, X
- Based in
- United States, North America
Influence Score 86.4editorial estimate, see how it is built
Audience size across LinkedIn, X, YouTube, podcasts and newsletters.
How much the audience actually reacts, comments, shares and subscribes.
Clinical, research, operating or investing track record behind the commentary.
Publishing cadence and how reliably they show up with original work.
Whether decision makers, policy and capital actually move on what they say.
Scores are subjective editorial estimates compiled by our research desk from public profiles and published work. They are opinion, not measurement, and they are not a judgement of any person's character or ability.
Also in AI & data science
This profile is compiled by our research desk from public sources and is published as editorial commentary. Want a correction, an update, or your profile removed? and see our corrections and removals policy.